Problem: Heterogeneous treatment effects

Solution: Our advanced Bayesian models capture individual patient differences and heterogeneous treatment effects. This adaptive approach tailors trial designs to reflect real-world variability, enhancing statistical power and yielding more reliable outcomes.

Problem: Powering rare disease research

Solution: Our adaptive Bayesian design reduces sample size requirements by leveraging sophisticated modelling. This enables robust trials for rare diseases that were previously unviable, opening new therapeutic avenues while ensuring statistical validity.

Problem: Variable yields and process instability.

Solution: Our technology incorporates high and medium throughput information to reduce iterations required to optimise full scale bioreactors.

Problem: Phase-to-Phase data wastage

Solution: Our Bayesian ML system integrates patient and treatment parameters across all phases, preserving and refining efficacy learnings so every participant counts towards the final insights.

Problem: Non-representative models

Solution: Incorporations of multivariate outcomes to the development of models increasing the representativeness of animal alternatives, tissue samples, and organs-on-a-chip.

Problem: Lack of early efficacy information

Solution: Our bespoke disease models integrate prior data with adaptive Bayesian methods to generate provisional efficacy signals during Phase I, facilitating informed decision-making and optimised progression into subsequent trial phases.

Problem: Suboptimal media

Solution: Our platform utilises deep learning to analyse complex media composition data and predict the optimal nutrient balance per unit cost. By iteratively refining formulations through simulation, we enhance cell proliferation, improve yield, and reduce production costs.

Problem: Suboptimal dosing strategies compromise efficacy

Solution: Our technology leverages dynamic optimisation techniques that continuously analyse patient data and drug responses to pinpoint the ideal dosing regimen. This ensures a balanced therapeutic window, maximising efficacy while minimising adverse effects.

Problem: High placebo effects obscuring drug efficacy.

Solution: Our adaptive trial models integrate placebo effects from the outset using sophisticated statistical methods. This enables a clearer, faster delineation of genuine treatment impact, reducing trial duration and improving decision-making.